arsenic trioxide has been researched along with Lymphoma in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (13.04) | 18.2507 |
| 2000's | 14 (60.87) | 29.6817 |
| 2010's | 6 (26.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, RW; Avram, MJ; Bally, MB; Barrett, SL; Chen, H; Gordon, LI; Jozefik, JK; Mazar, AP; O'Halloran, TV; Raja, MR; Shea, LD; Spaho, L; Winter, JN; Woodruff, TK | 1 |
| Hong, L; Kong, D; Qiao, Z; Shi, W; Sun, G; Zhang, Y; Zhao, H; Zhao, M | 1 |
| Bashford, J; Bradstock, K; Browett, P; Campbell, LJ; Catalano, A; Collins, M; Di Iulio, J; Filshie, R; Firkin, F; Grigg, A; Hertzberg, M; Hugman, A; Iland, HJ; Moore, J; Reynolds, J; Seldon, M; Seymour, JF; Supple, SG; Szer, J; Taper, J; Taylor, K; Tiley, C | 1 |
| Ahuja, HG; Bailey, HH; Chang, JE; Kahl, BS; Kim, K; Kolesar, JM; Rodriguez, GA; Sanchez, FA; Voorhees, PM; Werndli, J | 1 |
| Li, HM; Long, Y; Qing, C; Yu, MJ; Zhang, YL | 1 |
| Huang, R; Huang, X; Li, W; Li, X; Yang, X | 1 |
| Du, XY; Li, Y; Liu, XJ; Luo, JM; Wen, SP; Yang, L | 1 |
| Dong, ZR; Du, XY; Li, Y; Liu, XJ; Luo, JM; Wen, SP; Yang, JC; Yang, L; Yao, L | 1 |
| Bhalla, S; David, K; Evens, AM; Gordon, LI; Guo, D; O'Halloran, T; Platanias, LC; Prachand, S; Singh, AT; Winter, JN; Yang, S | 1 |
| Fan, LP; Fu, HY; Shen, JZ; Shen, SF; Zhou, HR | 1 |
| Gabrilove, J; Jing, Y; Liu, C; Wang, R; Waxman, S; Xia, L; Zhao, G | 1 |
| Amiot, L; Bernard, M; Drenou, B; Fardel, O; Fauchet, R; Lamy, T; Le Meur, A; Le Thiec, A; Lecureur, V | 1 |
| Chen, GQ; Chen, Z; Jing, Y; Styblo, M; Walton, F; Waxman, S; Weinberg, R; Zhou, L | 1 |
| Chan, R; Chen, D; Jing, Y; Waxman, S | 1 |
| Abou-Merhi, R; Arnoult, D; Bazarbachi, A; Dbouk, H; de Thé, H; El Hajj, H; El-Sabban, ME; Gessain, A; Hermine, O; Khoriaty, R; Mahieux, R; Munier, S | 1 |
| Bismar, TA; Diaz, Z; Laurenzana, A; Mann, KK; Miller, WH; Schipper, HM | 1 |
| Adamson, PC; Balis, FM; Blaney, SM; Fox, E; Goodspeed, W; Murgo, AJ; O'Brien, M; Razzouk, BI; Reaman, GH; Widemann, BC; Xiao, S | 1 |
| Li, HM; Li, LH | 1 |
| Dai, J; Jing, Y; Waxman, S; Weinberg, RS | 1 |
| Cai, X; Chen, GQ; Chen, SJ; Chen, Z; Dai, J; Huang, Y; Jia, PM; Jing, YK; Shen, YL; Shi, GY; Sun, YP; Tang, W; Wang, ZY; Waxman, S; Zhang, TD; Zhu, XH | 1 |
| Cheson, BD; McBee, WL; Murgo, AJ | 1 |
| Nie, L; Zhang, Y | 1 |
| Cai, X; Chen, G; Shen, Y | 1 |
1 review(s) available for arsenic trioxide and Lymphoma
| Article | Year |
|---|---|
[Progression of foundational and clinical studies on use of arsenic trioxide in treatment of lymphoma--review].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Lymphoma; Oxides | 2007 |
4 trial(s) available for arsenic trioxide and Lymphoma
| Article | Year |
|---|---|
A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lymphoma; Male; Middle Aged; Oxides; Recurrence; Treatment Outcome | 2015 |
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Australia; Consolidation Chemotherapy; Female; Humans; Leukemia, Promyelocytic, Acute; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Remission Induction; Treatment Outcome; Young Adult | 2015 |
Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study.
Topics: Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Female; Glutathione; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Oxides; Safety | 2009 |
Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.
Topics: Abdominal Pain; Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Constipation; Dermatitis; Dose-Response Relationship, Drug; Female; Headache; Humans; Hyperglycemia; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Lymphoma; Male; Nausea; Oxides; Pancreatitis; Pneumonia; Recurrence; Time Factors; Vomiting; Water-Electrolyte Balance | 2008 |
18 other study(ies) available for arsenic trioxide and Lymphoma
| Article | Year |
|---|---|
Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Female; Fertility; Humans; Lymphoma; Mice; Nanocapsules; Ovarian Follicle; Ovary; Oxides; Xenograft Model Antitumor Assays | 2013 |
[Apoptosis and cell cycle arrest in lymphoma Raji cells induced by arsenic trioxide].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Humans; Lymphoma; Oxides | 2008 |
[Effect of arsenic trioxide combined with adriamycin on the proliferation and apoptosis of human lymphoma cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; Humans; Lymphoma; Oxides | 2009 |
[Effect of As2O3 on demethylation of SHP-1 gene in human lymphoma cell line T2].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Lymphoma; Oxides; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-kit; RNA, Messenger; Signal Transduction | 2009 |
[As2O3 induces demethylation and up-regulates transcription of SHP-1 gene in human lymphoma cell line T2 cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; CpG Islands; DNA Methylation; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Oxides; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-kit; RNA, Messenger; Transcriptional Activation; Up-Regulation | 2009 |
Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanisms.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Glutathione; Humans; Lymphoma; Mitochondria; Oxides | 2010 |
[Arsenic trioxide reverses hypermethylation of p16 and activates its transcription in malignant lymphoma cell line CA46].
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; DNA Methylation; Genes, p16; Humans; Lymphoma; Oxides; Transcriptional Activation | 2010 |
Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Catalase; Cell Line, Tumor; Drug Synergism; Enzyme Activation; Ethacrynic Acid; Glutathione; Glutathione S-Transferase pi; Humans; Leukemia, Myeloid; Lymphoma; MAP Kinase Kinase 4; Membrane Potential, Mitochondrial; Myeloid Cell Leukemia Sequence 1 Protein; Oxides; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction | 2012 |
Potassium antimonyl tartrate induces caspase- and reactive oxygen species-dependent apoptosis in lymphoid tumoral cells.
Topics: Amino Acid Chloromethyl Ketones; Antimony Potassium Tartrate; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspases; Cell Survival; Coumarins; Cysteine Proteinase Inhibitors; Fluorescent Dyes; Humans; Lymphoma; Oligopeptides; Oxides; Reactive Oxygen Species; Tumor Cells, Cultured | 2002 |
Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Differentiation; Coculture Techniques; Glutathione Peroxidase; Hematopoietic Stem Cells; Humans; Hydrogen Peroxide; K562 Cells; Leukemia, Promyelocytic, Acute; Liver Neoplasms; Lymphoma; Methylation; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tumor Cells, Cultured | 2003 |
Buthionine sulfoximine enhancement of arsenic trioxide-induced apoptosis in leukemia and lymphoma cells is mediated via activation of c-Jun NH2-terminal kinase and up-regulation of death receptors.
Topics: Amino Acid Chloromethyl Ketones; Anthracenes; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Buthionine Sulfoximine; Caspase 3; Caspase Inhibitors; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Glutathione; Humans; Hydrogen Peroxide; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Leukemia; Lymphoma; Oxides; Receptors, TNF-Related Apoptosis-Inducing Ligand; Time Factors; U937 Cells | 2006 |
PS-341 or a combination of arsenic trioxide and interferon-alpha inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV-8-infected primary effusion lymphoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Herpesvirus 8, Human; Humans; Interferon-alpha; Lymphoma; Membrane Potential, Mitochondrial; NF-kappa B; Oxides; Protease Inhibitors; Pyrazines | 2007 |
Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Chromans; Cytochromes c; Drug Synergism; Humans; Liver; Lymphoma; Membrane Potential, Mitochondrial; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Oxides | 2007 |
Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cells, Cultured; Drug Synergism; Glutathione; Growth Inhibitors; Hematopoietic Stem Cells; HL-60 Cells; Humans; Lymphoma; Mice; Mice, Inbred Strains; Oxidation-Reduction; Oxides; Tumor Cells, Cultured | 1999 |
Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations.
Topics: Adenosine Triphosphate; Annexin A5; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspase 3; Caspases; Cell Division; Down-Regulation; Enzyme Activation; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Lymphocytes; Lymphoma; Mitochondria; Neoplasm Proteins; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins | 1999 |
Clinical trials referral resource. Clinical trials with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Female; Humans; Leukemia; Lymphoma; Multiple Myeloma; Neoplasms; Oxides; Urogenital Neoplasms; Uterine Cervical Neoplasms | 2000 |
Studies of apoptosis of malignant lymphoma cells induced by arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; DNA, Neoplasm; Dose-Response Relationship, Drug; Flow Cytometry; Humans; In Situ Nick-End Labeling; Jurkat Cells; Lymphoma; Oxides; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
[Glutathione synthesis inhibitor enhances arsenic trioxide-induced apoptosis].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Glutathione; Humans; Leukemia; Lymphoma; Oxides; Tumor Cells, Cultured | 1999 |